Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInvested CapitalMarket CapitalizationReturn on AssetsReturn on Capital EmployedReturn on Equity

Denali Therapeutics (DNLI) FCF Margin: 2018-2023

Historic FCF Margin for Denali Therapeutics (DNLI) over the last 6 years, with Sep 2023 value amounting to -7,058.48%.

  • Denali Therapeutics' FCF Margin fell 528563.00% to -7,058.48% in Q3 2023 from the same period last year, while for Sep 2023 it was -101.98%, marking a year-over-year increase of 12711.00%. This contributed to the annual value of -112.22% for FY2023, which is 12984.00% up from last year.
  • Denali Therapeutics' FCF Margin amounted to -7,058.48% in Q3 2023, which was down 17,838.85% from -39.35% recorded in Q2 2023.
  • Denali Therapeutics' 5-year FCF Margin high stood at 161.84% for Q4 2020, and its period low was -7,058.48% during Q3 2023.
  • In the last 3 years, Denali Therapeutics' FCF Margin had a median value of -547.76% in 2021 and averaged -1,134.58%.
  • Data for Denali Therapeutics' FCF Margin shows a peak YoY increase of 274,020bps (in 2019) and a maximum YoY decrease of 592,379bps (in 2019) over the last 5 years.
  • Quarterly analysis of 5 years shows Denali Therapeutics' FCF Margin stood at -1,079.11% in 2019, then spiked by 124,095bps to 161.84% in 2020, then plummeted by 70,960bps to -547.76% in 2021, then crashed by 20,603bps to -753.79% in 2022, then tumbled by 528,563bps to -7,058.48% in 2023.
  • Its FCF Margin was -7,058.48% in Q3 2023, compared to -39.35% in Q2 2023 and -184.62% in Q1 2023.